Efficacy of clopidogrel as inhibitor of ADP-induced platelet aggregation. A study in patients with coronary artery disease;Eficacia del clopidogrel como inhibidor de la agregacion plaquetaria dependiente de ADP. Un estudio en individuos con enfermedad arterial coronaria

Archivos del Instituto de Cardiologia de Mexico

Volumn 70, Issue 5, 2000, Pages 472-480

  Izaguirre Avila, R ^a   De la Pena, A ^a   Gonzalez Pacheco, H ^a   Ramirez Gutierrez, A ^a   Gonzalez Valdez, H ^a   Quiroz, A ^a   Cortina, E ^a   Huerta, M ^a   Lupi, E ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Antiplatelet drugs; Coronary artery disease; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLEEDING TIME; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADULT; AGED; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0033679826     PISSN: 00203785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mortality by cause for eight regions of the world: Global Burden of Disease Study
2. Platelet-Endothelium interactions
3. Thrombosis and coagulation abnormalities in the acute coronary syndromes
4. Colaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. A randomized trial comparing ticlopidine hidrochloride with aspirin for the prevention of stroke in high-risk patients
6. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
7. Antiplatelet treatment with ticlopidine in unestable angine: A controlled multicenter clinical trial
8. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (Caprie)
9. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
10. Platelet function testing: An improved approach utilizing lumi-aggregation and interactive computer system
11. The PSY1 receptor, necessary but no sufficient to suport full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
12. Specific inhibition of ADP-induced platelet aggregation by Clopidogrel in vitro
13. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
14. Characteristics of rat platelets and relative contributions of platelets and blood coagulation to hemostasis
15. Flow citometry analysis of intracellular VASP phosphorylation, the assessment of activating and inhibitory signal transduction patways in human platelets-definition and detection of ticlopidine/clopidogrel effects
16. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects
17. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis
18. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients
19. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects
20. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
21. Clopidogrel versus ticlopidine after intracoronary stent placement
22. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents
23. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
24. Shear-induced platelet aggregation in cerebral ischemia
25. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease
26. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis